Evidence map›Paper›PMID 41584040›Full record

ArticleJournal of Cancer2026

Spatial Profiling and Prognostic Role of Tumor-Infiltrating CD8+ T and CD20+ B Cells in Metastatic Clear Cell Renal Cell Carcinoma Treated with Sequential Tyrosine Kinase Inhibitors and Nivolumab.

Andriy Trailin, Lenka Červenková, Petr Hošek, Kristýna Pivovarčíková, Michaela Tkadlecová, Petr Stránský, Kari Hemminki, Ondřej Fiala

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andriy TrailinLaboratory of Translational Cancer Genomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1665/76, 32300 Pilsen, Czech Republic.
Lenka ČervenkováLaboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1665/76, 32300 Pilsen, Czech Republic.
Petr HošekLaboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1665/76, 32300 Pilsen, Czech Republic.
Kristýna PivovarčíkováDepartment of Pathology, Faculty of Medicine in Pilsen, University Hospital Pilsen, Charles University in Prague, 30460 Pilsen, Czech Republic.
Michaela TkadlecováDepartment of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Czech Republic, Alej Svobody 80, 304 60 Pilsen.
Petr StránskýDepartment of Urology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Czech Republic, Edvarda Beneše 1128/13, 301 00 Pilsen, Czech Republic.
Kari HemminkiDepartment of Cancer Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Ondřej FialaLaboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1665/76, 32300 Pilsen, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

immune checkpoint inhibitorsmetastatic renal cell carcinomaprogression-free survivaltumor-infiltrating lymphocytestyrosine kinase inhibitors

Identifiers

PMID41584040
PMCPMC12825419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.